Federal Panel Endorses Ticagrelor for ACS

ADELPHI, Md. (MedPage Today) — An FDA advisory panel has voted overwhelmingly to recommend approval of AstraZeneca’s investigational antiplatelet ticagrelor (Brilinta), saying it appears more effective than clopidogrel (Plavix) for patients with acute coronary syndrome who will be treated either medically or with PCI.


Read more

Related posts

Leave a Reply